Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hemodialysis Pilot Studies Consortium Resource Report Resource Website |
Hemodialysis Pilot Studies Consortium (RRID:SCR_017468) | HDPSC | consortium, data or information resource, organization portal, portal | Consortium to design and conduct pilot and feasibility studies of novel therapies to reduce morbidity and mortality for patients treated with maintenance hemodialysis. Data Coordinating Center (DCC) for consortium provides scientific expertise and operational support for pilot studies that will be conducted at HDPSC Participating Clinical Centers. Data Coordinating Center for Hemodialysis Pilot Studies Consortium. | Novel, therapy, reduce, morbidity, patient, maintenance, hemodialysis, data, coordinating, center | has parent organization: University of Pennsylvania Perelman School of Medicine; Pennsylvania; USA | NIDDK ; NIH |
SCR_017468 | SciCrunch Registry | 2026-11-14 11:25:10 | 0 | |||||||||
|
Motif Mutation Analysis for Regulatory Genomic Elements Resource Report Resource Website 500+ mentions |
Motif Mutation Analysis for Regulatory Genomic Elements (RRID:SCR_021902) | MMARGE | data analysis software, data processing software, software application, software resource, software toolkit | Software package that integrates genome wide genetic variation with epigenetic data to identify collaborative transcription factor pairs. Optimized to work with chromatin accessibility assays such as ATAC-seq or DNase I hypersensitivity, as well as transcription factor binding data collected by ChIP-seq. Used to identify combinations of cell type specific transcription factors while simultaneously interpreting functional effects of non-coding genetic variation. | genome wide genetic variation, epigenetic data, identify collaborative transcription factor pairs, interpreting functional effects, non-coding genetic variation | NCI CA173903; NHLBI R00 123485; NIDDK DK091183; NIGMS GM085764 |
PMID:29893919 | Free, Available for download, Freely available | SCR_021902 | SciCrunch Registry | 2026-11-14 11:26:23 | 608 | ||||||||
|
FunGene Resource Report Resource Website 50+ mentions |
FunGene (RRID:SCR_018749) | analysis service resource, data or information resource, data repository, database, production service resource, service resource, software resource, software toolkit, storage service resource | Functional gene pipeline and repository. Functional gene repository provides collections of genes in interactive platform, while functional gene pipeline offers suite of tools for functional gene amplicon processing and analysis. Together they enable key steps in functional gene based microbial community analysis, from target selection and primer analysis to amplicon processing and ecological discovery. | Gene processing, microbial ecology, functional genes, amplification primers, phylogeny, biogeochemical cycles, amplicon analysis, ecological discovery, microbial community | has parent organization: Michigan State University; Michigan; USA | NIDDK UH3 DK083993; NIEHS ; NIEHS P42 ES004911; Office of Science U.S. Department of Energy ; USDA National Institute of Food and Agriculture |
PMID:24101916 | Free, Freely available | SCR_018749 | SciCrunch Registry | FunGene Pipeline | 2026-11-14 11:25:23 | 58 | |||||||
|
Diabetic Foot Consortium Resource Report Resource Website |
Diabetic Foot Consortium (RRID:SCR_018914) | DFC | consortium, data or information resource, disease-related portal, organization portal, portal, topical portal | Group of academic institutions committed to studying diabetic foot conditions, such as foot ulcers and wound healing, to develop predictive biomarkers which can be later used to create better treatment plans and improve health and quality of life for people living with diabetes. | Academic institution group, diabetic, diabetic foot, diabetic foot condition, foot ulcer, wound healing, biomarker |
is related to: Indiana University; Indiana; USA is related to: University of Pittsburgh; Pennsylvania; USA is related to: University of Miami; Florida; USA is related to: University of California at San Francisco; California; USA is related to: Stanford University; Stanford; California is related to: University of Michigan; Ann Arbor; USA |
diabetic | NIDDK | SCR_018914 | SciCrunch Registry | 2026-11-14 11:25:26 | 0 | ||||||||
|
Urinary Stone Disease Research Network Resource Report Resource Website |
Urinary Stone Disease Research Network (RRID:SCR_019059) | USDRN | data or information resource, disease-related portal, portal, topical portal | Portal for research on urinary stones in adults and children in order to learn more about who forms kidney stones, treatments and prevention. Network comprises of experts including adult and pediatric urologists, adult and pediatric nephrologists, pediatricians, emergency department physicians, clinical trialists, nutritionists, behavioral scientists, and radiologists. Duke Clinical Research Institute is Scientific Data Research Center and with clinical sites including University of Pennsylvania Children Hospital of Philadelfia, University of Texas Southwestern Medical Center, University of Washington, Washington University in St. Louis, work together in planning, executing, and analyzing results from USDRN studies. | Urinary stone, kidney stone, kidney, treatment, prevention, urologist, nephrologist, pediatrician, clinical trial, data |
is related to: Duke University School of Medicine; North Carolina; USA is related to: University of Pennsylvania; Philadelphia; USA is related to: University of Texas System; Texas; USA is related to: Washington University in St. Louis; Missouri; USA is related to: University of Washington; Seattle; USA |
Kidney stones | NIDDK ; NIH |
Free, Freely available | SCR_019059 | SciCrunch Registry | 2026-11-14 11:25:28 | 0 | |||||||
|
MaAsLin2 Resource Report Resource Website 100+ mentions |
MaAsLin2 (RRID:SCR_023241) | software resource, software toolkit | SoftwareR package that identifies microbial taxa correlated with factors of interest using generalized linear models and mixed models.Used for efficiently determining multivariable association between clinical metadata and microbial meta'omic features. | Microbiome Multivariable Associations with Linear Models, | NHGRI R01HG005220; NIAID U19AI110820; NIDDK R24DK110499; NIDDK U54DK102557; NSF DEB-2028280 |
DOI:10.1371/journal.pcbi.1009442 | Free, Available for download, Freely available | https://huttenhower.sph.harvard.edu/maaslin/ | SCR_023241 | SciCrunch Registry | 2026-11-14 11:29:18 | 212 | ||||||||
|
ataqv Resource Report Resource Website 1+ mentions |
ataqv (RRID:SCR_023112) | software resource, software toolkit | Software package for QC and visualization of ATAC-seq results. Used to examine aligned reads and report basic metrics, including reads mapped in proper pairs, optical or PCR duplicates, reads mapping to autosomal or mitochondrial references, ratio of short to mononucleosomal fragment counts, mapping quality, various kinds of problematic alignments. | QC of ATAC-seq results, visualization of ATAC-seq results, examine aligned reads, mapping quality, | American Diabetes Association Pathway to Stop Diabetes ; NHGRI T32 HG00040; NIDDK R01 DK-117960; NIDDK T32 DK101357; University of Michigan Rackham Predoctoral Fellowship |
PMID:32213349 | Free, Available for download, Freely available | https://parkerlab.github.io/ataqv/demo/ | SCR_023112 | SciCrunch Registry | 2026-11-14 11:29:18 | 7 | ||||||||
|
mtradeR Resource Report Resource Website 1+ mentions |
mtradeR (RRID:SCR_022977) | software resource, software toolkit | Software R package implements Joint model with Matching and Regularization and simulation pipeline. Used to test association between taxa and disease risk, and adjusted for correlated taxa screened by pre-selection procedure in abundance and prevalence, individually. | test association between taxa and disease risk, correlated taxa screening, taxa and disease risk | American Lebanese Syrian Associated Charities ; NCI CA21765; NIDDK U24DK097771 |
PMID:36123651 | Free, Available for download, Freely available | SCR_022977 | SciCrunch Registry | Metagenomic TRajectory Analysis with Disease Endpoint and Risk factors | 2026-11-14 11:29:17 | 1 | ||||||||
|
Irritable Bowel Syndrome Outcome Study Resource Report Resource Website |
Irritable Bowel Syndrome Outcome Study (RRID:SCR_001504) | IBSOS | clinical trial, resource | Multi-center placebo-controlled randomized clinical trial to assess the short-term and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome (IBS) using two treatment delivery systems: self administered CBT and therapist administered CBT. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable gastrointestinal disorders. | gastrointestinal disorder, cognitive behavior therapy, self-management, self-administered |
is listed by: NIDDK Information Network (dkNET) has parent organization: University at Buffalo; New York; USA |
Irritable bowel syndrome | NIDDK 5U01DK077738-07 | PMID:22846389 | Free | nlx_152839 | SCR_001504 | SciCrunch Registry | 2026-11-14 11:29:26 | 0 | |||||
|
Folic Acid for Vascular Outcome Reduction in Transplantation Resource Report Resource Website 1+ mentions |
Folic Acid for Vascular Outcome Reduction in Transplantation (RRID:SCR_001505) | FAVORIT | clinical trial, resource | Multi-center, randomized, double blind controlled clinical trial to determine whether treatment with a standard multivitamin augmented with high doses of folic acid, vitamin B6 and vitamin B12 reduces the rate of cardiovascular disease outcomes in renal transplant recipients relative to participants receiving a similar multivitamin that contains no folic acid. This study hopes to show that by reducing the level of homocysteine in the body, the risk of heart disease is also reduced among kidney transplant patients. | multivitamin, folic acid, vitamin b6, vitamin b12, outcome, homocysteine, adult human, middle adult human, late adult human, vitamin, bibliography |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Cardiovascular disease, Kidney transplant recipient | NIDDK U01DK061700 | PMID:16923411 | Free, Freely available | nlx_152827 | http://www.cscc.unc.edu/favorit/ | http://www.cscc.unc.edu/favorit/favdescrip.htm | SCR_001505 | SciCrunch Registry | Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) | 2026-11-14 11:29:26 | 1 | ||
|
Family Investigation of Nephropathy of Diabetes Resource Report Resource Website |
Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) | FIND, F.I.N.D. | clinical trial, resource | Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease | genetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinical |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
NIDDK 5R01DK053591 | PMID:15642484 | Free, Freely available | nlx_152825 | https://www.niddkrepository.org/studies/find/ | SCR_001525 | SciCrunch Registry | Family Investigation of Nephropathy and Diabetes (F.I.N.D.), Family Investigation of Nephropathy & Diabetes | 2026-11-14 11:29:26 | 0 | ||||
|
HALT PKD Resource Report Resource Website 1+ mentions |
HALT PKD (RRID:SCR_001529) | HALT PKD, HALT-PKD | clinical trial, resource | Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease. | treatment, renal function, lisinopril, placebo, telmisartan, male, female, adolescent, adult human |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Washington University School of Medicine in St. Louis; Missouri; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK062408 | Free, Freely available | nlx_152832 | https://www.niddkrepository.org/studies/halt-pkd/ | http://www.pkd.wustl.edu/pkdtn/ | SCR_001529 | SciCrunch Registry | Polycystic Kidney Disease-Treatment Network | 2026-11-14 11:29:26 | 1 | |||
|
Clinical Islet Transplantation Study Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Study (RRID:SCR_001515) | CIT Study | clinical trial, resource | Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation. | islet transplantation, islet, insulin, beta cell, pancreas, autoimmune, clinical | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK U01DK070431 | Free, Freely available | nlx_152840 | SCR_001515 | SciCrunch Registry | Clinical Islet Transplantation Trial, Islet Transplantation Trials for Type 1 Diabetes | 2026-11-14 11:29:26 | 5 | |||||
|
RiVuR Resource Report Resource Website 1+ mentions |
RiVuR (RRID:SCR_001539) | RIVUR | clinical trial, resource | Multicenter, randomized, double-blind, placebo-controlled trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). The basic eligibility criteria are: (1) age at randomization of at least 2 months, but less than 6 years, (2) a diagnosed first febrile or symptomatic UTI within 42 days prior to randomization that was appropriately treated, and (3) presence of Grade I-IV VUR based on voiding cystourethrogram (VCUG). Patients will be randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. In addition, patients will be evaluated for secondary endpoints related to renal scarring and antimicrobial resistance. Scarring will be determined based on renal scintigraphy by 99mTc dimercaptosuccinic (DMSA) scan. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. | child, antimicrobial prophylaxis, placebo, antibiotic, renal scarring, pediatric, trimethoprim-sulfamethoxazole, intervention, kidney, antibiotic resistance, young human, infant, bibliography, clinical, trimethoprim, sulfamethoxazole |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Vesico-ureteral reflux, Urinary tract infection | NIDDK | PMID:19570724 PMID:19018048 PMID:18076937 PMID:19018047 PMID:19086141 |
Free, Freely available | nlx_152848 | http://www.cscc.unc.edu/rivur/ | SCR_001539 | SciCrunch Registry | Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR), Randomized Intervention for Children with Vesicoureteral Reflux, Randomized Intervention for Vesicoureteral Reflux | 2026-11-14 11:29:27 | 1 | |||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | SciCrunch Registry | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-11-14 11:29:33 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | clinical trial, resource | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | SciCrunch Registry | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-11-14 11:29:32 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | clinical trial, resource | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | SciCrunch Registry | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-11-14 11:29:33 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | clinical trial, resource | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | SciCrunch Registry | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-11-14 11:29:32 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | SciCrunch Registry | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-11-14 11:29:32 | 0 | ||||
|
Diabetes Control and Complications Trial Resource Report Resource Website |
Diabetes Control and Complications Trial (RRID:SCR_006805) | DCCT | clinical trial, data or information resource, database, resource | Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk | blood glucose, adolescent, young human, middle adult human, longitudinal, eye disease, kidney disease, nerve disease, cardiovascular disease, heart attack, stroke, blood pressure, blood lipid, complication |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository is related to: Epidemiology of Diabetes Interventions and Complications is related to: Epidemiology of Diabetes Interventions and Complications is related to: NIDDK Information Network (dkNET) has parent organization: National Diabetes Information Clearinghouse |
Type 1 diabetes, Diabetes | NIDDK | nlx_152798 | SCR_006805 | SciCrunch Registry | DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study | 2026-11-14 11:29:33 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.